For anyone in Rougé looking to source CJC-1295, the first thing to know is that this compound is available only through an online research supply market. The upside of this online-only market is that serious vendors are judged entirely by their analytical documentation, giving researchers access to better quality signals than any local market ever offers. Separating quality CJC-1295 from the rest of the market depends on three things: an HPLC chromatogram showing ≥98% purity, mass spec data verifying the correct molecular weight, and a batch-specific endotoxin panel. This guide gives Rougé researchers the methodology to evaluate CJC-1295 vendors systematically and source verified-quality CJC-1295 with confidence.
The Science Behind CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Rougé researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Buying CJC-1295: Quality Markers to Look For
Quality CJC-1295 sourcing begins with a straightforward question: does this vendor make batch-matched COAs available before purchase? Vendors who do are demonstrating research-grade standards. When reviewing a CJC-1295 COA, verify: the batch number traces to your order, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are below the threshold for research use. The combination of peer feedback and direct document verification is the gold standard for CJC-1295 sourcing — community feedback surfaces recurring issues no single purchase reveals, and vice versa. The lyophilised (freeze-dried) form of CJC-1295 is always preferable to liquid pre-made solutions — lyophilised powder maintains stability for years when frozen, while liquid preparations break down rapidly even under refrigeration.
Order CJC-1295 — ships to Rougé
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means safety data comes from animal studies, in-vitro work, and limited human observations — rather than the large-scale clinical data that informs approved drug safety. Lyophilised CJC-1295 should be placed in the freezer at −20°C straight away; do not freeze and thaw reconstituted CJC-1295 multiple times by aliquoting into single-use portions. Verify the endotoxin level in your CJC-1295 batch COA before any protocol involving administration — look for results expressed as EU/mg or EU/mL and compare against acceptable research limits for your application. The research literature on CJC-1295 should be reviewed carefully before planning any study — study designs, dosing ranges, and outcome measures vary significantly and results do not always generalise across models.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
